{"id":"NCT03106779","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","officialTitle":"A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-26","primaryCompletion":"2020-05-25","completion":"2024-12-04","firstPosted":"2017-04-10","resultsPosted":"2022-02-15","lastUpdate":"2025-04-08"},"enrollment":233,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Myelogenous Leukemia"],"interventions":[{"type":"DRUG","name":"Asciminib","otherNames":["ABL001"]},{"type":"DRUG","name":"Bosutinib","otherNames":[]}],"arms":[{"label":"Asciminib","type":"EXPERIMENTAL"},{"label":"Bosutinib","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs.\n\nPatients intolerant to the most recent TKI therapy must have had BCR-ABL1 ratio \\> 0.1% IS at screening and patients failing their most recent TKI therapy must have met the definition of treatment failure as per the 2013 European LeukemiaNet (ELN) recommendations.\n\nPatients with documented treatment failure as per 2013 ELN recommendations while on bosutinib treatment had the option to switch to asciminib treatment within 96 weeks after the last patient has been randomized on study.","primaryOutcome":{"measure":"Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks","timeFrame":"24 weeks","effectByArm":[{"arm":"Asciminib","deltaMin":40,"sd":null},{"arm":"Bosutinib","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.029"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":20},"locations":{"siteCount":88,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Lebanon","Mexico","Netherlands","Romania","Russia","Saudi Arabia","Serbia","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40334072","37431294","36168187","35764773","34407542"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":156},"commonTop":["Diarrhoea","Nausea","Thrombocytopenia","Neutropenia","Headache"]}}